Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27002872 | 0.83 | ATM (0.34) | ATMMEN1KMT2AGAA | |
| SCHEMBL2063033 | 0.81 | ATM (0.35) | ATMMEN1KMT2AGAA | |
| SCHEMBL29338015 | 0.73 | MAPK1 (0.33) | ATMMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL28969335 | 0.72 | MEN1 (0.46) | MEN1KMT2ALMNAGAA | |
| SCHEMBL29338016 | 0.71 | GAA (0.32) | ATMMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL27670024 | 0.71 | MEN1 (0.34) | ATMMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL8384735 | 0.71 | PKM (0.39) | ATMMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL30259473 | 0.70 | GAA (0.33) | ATMMAPK1MEN1KMT2AALDH1A1 | |
| SCHEMBL939974 | 0.68 | POLB (0.44) | MEN1KMT2ATSHRGAA | |
| SCHEMBL13981849 | 0.68 | ALDH1A1 (0.39) | ATMMAPK1MEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | LIFEARC (GB) | 2024-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240239790-A1 | 7-Morpholino-1,6-Naphthyridin-5-yl Derivatives and Pharmaceutical Compositions Thereof Useful as DNA-PK Inhibitor | DCK, ERCC2, POLK | ATM 38/4885MAPK1 1394/4885MEN1 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.